Daily Medication Pearl: Exkivity (Mobocertinib) for Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Indication: Exkivity is a kinase inhibitor indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.

Insight:

• Dosing: The recommended dosage is 160 mg orally once daily, with or without food.
• Dosage form: 40 mg capsules
• Adverse events: The most common (>20%) adverse reactions are diarrhea, rash, nausea, stomatitis, vomiting, decreased appetite, paronychia, fatigue, dry skin, and musculoskeletal pain.
• Mechanism of action: Mobocertinib is a kinase inhibitor of the epidermal growth factor receptor (EGFR) that irreversibly binds to and inhibits EGFR exon 20 insertion mutations at lower concentrations than wild type (WT) EGFR.
• Manufacturer: Takeda

References

• label (fda.gov)
• EXKIVITY™ (mobocertinib) | Now Approved